News

Fixed-Dose Combo Therapy Boosts BP Control : Patients in the as-yet unblinded ACCOMPLISH had the highest overall control rates ever reached in a U.S. trial.


 

Dr. Jamerson responded by noting that the average age of the ACCOMPLISH cohort was 68 years, but added that the final data will be analyzed to determine exactly how many hypotensive events are drug-related.

The study is powered to show that the combination of benazepril and amlodipine will reduce cardiovascular morbidity and mortality in patients with high-risk hypertension by 15%, compared with the combination of benazepril and HCTZ. Theoretical research suggests that a combination of ACE inhibitors and calcium-channel blockers might confer an additional benefit, as they have been shown independently to increase vascular nitric oxide production, Dr. Jamerson said.

'For more than 2 decades, too many clinicians have chanted the mantra, “start low, go slow.”' DR. JAMERSON

Pages

Recommended Reading

Aliskiren's Benefits May Go Beyond BP Control
MDedge Cardiology
Big Gains in BP Control Seen Since JNC-7
MDedge Cardiology
Chinese Study Finds No Blood Pressure J-Curve
MDedge Cardiology
Biofeedback Cuts BP in Type 2 Diabetes
MDedge Cardiology
Hypertension in Pregnancy Tied to Late CV Events
MDedge Cardiology
Early BP Screening in Offspring of Stroke Patients Warranted
MDedge Cardiology
Sleep Apnea and HT Tied in Kidney Disease
MDedge Cardiology
Weight Loss in Prehypertension Cuts Risks, Helps Avoid Medication
MDedge Cardiology
Aldosterone Tied to Metabolic Syndrome in Hypertensive Blacks
MDedge Cardiology
Pediatric Hypertension Is Linked To Sleep-Disordered Breathing
MDedge Cardiology